Adam Keeney

Head of Corporate Development · Biogen

Biotechnology

Adam Keeney leads corporate development at Biogen, combining discovery research, pharmaceutical business development and prior experience as NodThera’s chief executive officer.

Last reviewed: Nov 2, 2026

Adam Keeney

Head of Corporate Development
Biogen

Last Reviewed: November 2, 2026

Executive Summary

Adam Keeney leads corporate development at Biogen, combining discovery research, pharmaceutical business development and prior experience as NodThera’s chief executive officer.

Career Highlights

  • Joined Biogen as executive vice president and head of corporate development in April 2023.
  • Led NodThera as CEO from 2018 to 2022.
  • Previously led Sanofi Genzyme business development and worked at Johnson & Johnson and Lundbeck.

Professional Journey

Keeney began his industry career as a discovery scientist at Lundbeck. He subsequently moved into business development, working at Johnson & Johnson from 2004 to 2013 in roles with increasing responsibility.

From 2014 to 2018, he worked at Sanofi, with responsibility for all of Sanofi Genzyme’s business development activities. His remit covered early-stage and later-stage transactions across therapeutic areas and treatment modalities.

Keeney became chief executive officer of NodThera in 2018. He led the clinical-stage biotechnology company, whose research focused on chronic inflammation, until 2022. This added responsibility for running a biotech business to his earlier scientific and transaction experience.

In April 2023, Keeney joined Biogen as executive vice president and head of corporate development and became a member of its executive committee.

Education

Keeney earned a B.Sc. with honors from the University of Leeds and a Ph.D. in neuropharmacology from the University of Nottingham.